Nelfinavir and Cariprazine: Interaction Details
AI-assisted, pharmacist-reviewed · AI content regenerated Jul 16, 2026 · Source data updated Jul 16, 2026 · Sources: FDA labeling, DDInter 2.0, cited literature
Nelfinavir
Cariprazine
How we grade severity & evidence
Severity levels
- Contraindicated: These should generally not be used together.
- Major: Potentially serious — often needs a change or close monitoring.
- Moderate: Can be significant — usually manageable with monitoring.
- Minor: Usually limited clinical impact.
Evidence grades
- Established: Well documented — supported by controlled studies or strong clinical data.
- Probable: Good supporting evidence, though not definitively proven.
- Suspected: Some evidence suggests this interaction, but it is not well established.
- Possible: Limited or conflicting evidence; the interaction may occur.
- Theoretical: Predicted from the drugs' pharmacology; not yet confirmed in people.
Ratings come from the documented interaction literature and are reviewed by a pharmacist. They describe the documented risk of the combination, not what will necessarily happen to you — your dose, timing, and health picture all matter.
Here's what's going on. Your body normally breaks down cariprazine (Vraylar) using an enzyme called CYP3A4. Nelfinavir (Viracept) strongly blocks that enzyme. When it's blocked, cariprazine and its long-lasting active form build up in your body, so you may feel more of its effects and side effects, like drowsiness, restlessness, dizziness, or muscle stiffness.
The good news: this is very manageable. If you take both, your care team can simply use a lower or less frequent cariprazine dose and keep an eye on how you're doing. Please don't change anything on your own, but do check in with your pharmacist or doctor so they can tailor your dose safely.
Mechanism: Nelfinavir is a strong CYP3A4 inhibitor; cariprazine is a CYP3A4 substrate. Inhibition reduces clearance, increasing exposure to cariprazine and its active metabolite didesmethylcariprazine. Ketoconazole data showed AUC and Cmax rose ~100%. Evidence probable, severity major.
- Direction: increased cariprazine exposure and pharmacodynamic/adverse effects (EPS, akathisia, sedation).
- Initiating cariprazine with the inhibitor (schizophrenia/bipolar mania): 1.5 mg every 3 days, may increase to 1.5 mg every other day per response.
- Bipolar depression/adjunctive MDD: 1.5 mg every 3 days.
- Adding inhibitor to stable dose: 1.5 or 3 mg/day to 1.5 mg every 3 days; 4.5 or 6 mg/day to 1.5 mg every other day.
- On inhibitor discontinuation: cariprazine dose may need to be increased per tolerability.
What happens
Increased exposure to cariprazine and its active metabolite, didesmethylcariprazine
Interaction Deep Dive
When cariprazine (a CYP3A4 substrate) is given together with a potent CYP3A4 inhibitor, the levels of both cariprazine and its active metabolite, didesmethylcariprazine, may rise. In interaction studies, giving cariprazine alongside ketoconazole (a strong CYP3A4 inhibitor) produced an AUC and Cmax increase of roughly 100%. For this reason, when cariprazine is being started in a patient already receiving a strong CYP3A4 inhibitor (for schizophrenia or bipolar mania), begin with 1.5 mg orally every 3 days, and if warranted by clinical response and tolerability, raise the dose to 1.5 mg orally every other day. If a strong CYP3A4 inhibitor is present during treatment for bipolar depression or as adjunctive therapy for MDD, the dose is 1.5 mg orally every 3 days. If a strong CYP3A4 inhibitor is introduced in a patient already on a stable cariprazine regimen, dose adjustments are as follows: those taking 1.5 or 3 mg once daily should have their cariprazine changed to 1.5 mg orally every 3 days upon starting the inhibitor, while those taking 4.5 or 6 mg once daily should be switched to 1.5 mg orally every other day. Once the strong CYP3A4 inhibitor is stopped, it may be necessary to raise the cariprazine dose according to clinical response and tolerability1.
Why it happens (mechanism)
Inhibition of CYP3A4-mediated metabolism of cariprazine
How to manage this interaction
This can be managed by adjusting your cariprazine dose and monitoring you more closely. Keep taking both medicines exactly as prescribed unless your care team tells you otherwise.
- Because nelfinavir raises cariprazine levels, your team will typically use a lower or less frequent cariprazine dose (for example, spacing doses further apart) and individualize it to your response.
- If the nelfinavir is later stopped, your cariprazine dose may need to be raised again.
- Tell your pharmacist or prescriber if you notice more drowsiness, restlessness, tremor, muscle stiffness, or dizziness, so they can fine-tune your dose.
Management is individual — confirm any change with your pharmacist or prescriber.
Literature reports
1 report — tap to read
a) In drug interaction studies, giving cariprazine 0.5 mg/day together with ketoconazole 400 mg/day led to an increase in total cariprazine AUC and Cmax of approximately 100% 1.
Common questions
Can I take Nelfinavir and Cariprazine together?
Nelfinavir blocks the enzyme that clears cariprazine, so cariprazine levels and side effects can rise; your care team can manage this by lowering or spacing out your cariprazine dose and watching how you respond. Don't change either medicine on your own. Always confirm with your pharmacist or prescriber before making any change.
How serious is the Nelfinavir and Cariprazine interaction?
It is rated major. Potentially serious — often needs a change or close monitoring.
How quickly could this interaction happen?
The documented onset is "unspecified". The timing of this interaction is not well characterized.
How is the Nelfinavir and Cariprazine interaction managed?
This can be managed by adjusting your cariprazine dose and monitoring you more closely. Keep taking both medicines exactly as prescribed unless your care team tells you otherwise. Because nelfinavir raises cariprazine levels, your team will typically use a lower or less frequent cariprazine dose (for example, spacing doses further apart) and individualize it to your response. If the nelfinavir is… Management is individual — always follow your own care team's guidance.
How strong is the evidence for this interaction?
The evidence is graded "probable". Good supporting evidence, though not definitively proven.
Questions for your pharmacist
- Does my dose of Nelfinavir or Cariprazine need adjusting while I take them together?
- What symptoms should prompt me to call you or my prescriber right away?
- Does the timing of my doses matter for this combination?
- Is there a safer alternative to one of these medications for me?
References (1)
- Product Information: VRAYLAR(R) oral capsules, cariprazine oral capsules. AbbVie Inc. (per FDA), North Chicago, IL, 2024. DailyMed
Keep reading about Nelfinavir
Keep reading about Cariprazine
Check another combination
Our instant two-drug interaction checker is almost here.
Still have questions about this combination?
Every question gets a real answer from a licensed pharmacist — free, and usually within a day.
Ask the pharmacist